Capricorn resignations a blow to New Med merger plans
The disputed deal is playing out in public, as Capricorn’s board and activist shareholder Palliser both issue statements and rebuttals
The proposed merger of London-listed Capricorn Energy and Israel’s Newmed may have been scuppered by shareholder opposition. Five of the Capricorn board’s nine members resigned in late January, including the chairman and CEO. Another two board members, including the CFO, have committed to resign before 1 February. That is when shareholders will meet—as requested by shareholder and London-based fund Palliser Capital—to approve replacement board members, instead of voting on the merger deal, as was previously scheduled. The merger vote itself has now been pushed back to 22 February, which Capricorn says will allow “a reconstituted board to assess the proposed Newmed combination alongside other
Also in this section
11 February 2026
Panellists from three LNG buyers at LNG2026 in Doha outlined their evolving procurement strategies as they navigate heightened market volatility
11 February 2026
North African producer plans to boost output by early 2030, with Europe its number one priority as export destination
11 February 2026
Maritime leaders at LNG2026 warned of the dangers of over-regulation on competitiveness, sustainability and innovation
10 February 2026
The country has opened bidding on 50 blocks in a new licensing round but will face competition for attention and will need to address concerns about security and legislation






